Ravulizumab ARTEMIS: 555 Patients, Six Terminations, and a Mechanism That Did Not Travel
Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
Witfire Coverage
Category: Clinical Catalysts
OX40 Atopic Dermatitis: A Drug Class Ended in 175 Days and 8,185 Patients
Witfire Elite · Clinical Catalysts · Registry Analysis OX40 atopic dermatitis development is over. Two companies, two mechanisms, 175 days. The press releases said…